Strs Ohio Takes $566,000 Position in Monte Rosa Therapeutics, Inc. $GLUE

Strs Ohio acquired a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) during the 4th quarter, Holdings Channel reports. The firm acquired 36,100 shares of the company’s stock, valued at approximately $566,000.

Several other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Monte Rosa Therapeutics by 8.6% during the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after purchasing an additional 257,547 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock worth $50,000 after acquiring an additional 776 shares in the last quarter. CWM LLC increased its position in shares of Monte Rosa Therapeutics by 13.6% during the fourth quarter. CWM LLC now owns 29,444 shares of the company’s stock worth $462,000 after acquiring an additional 3,536 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth about $778,000. Finally, Brookwood Investment Group LLC bought a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth about $306,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Insiders Place Their Bets

In other Monte Rosa Therapeutics news, insider Philip Nickson sold 5,845 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $17.69, for a total value of $103,398.05. Following the completion of the sale, the insider directly owned 55,000 shares of the company’s stock, valued at approximately $972,950. This represents a 9.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the sale, the chief executive officer directly owned 613,471 shares of the company’s stock, valued at $10,993,400.32. The trade was a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 37,150 shares of company stock valued at $668,694. Corporate insiders own 6.90% of the company’s stock.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock opened at $19.39 on Friday. Monte Rosa Therapeutics, Inc. has a 52-week low of $3.51 and a 52-week high of $25.77. The company has a 50-day simple moving average of $17.69 and a two-hundred day simple moving average of $17.40. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -13.10 and a beta of 1.62.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 52.22% and a negative net margin of 302.69%.The firm had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. On average, sell-side analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GLUE. Guggenheim decreased their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Piper Sandler reissued an “overweight” rating and set a $37.00 target price (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Wells Fargo & Company decreased their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Finally, Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Monte Rosa Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $32.80.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.